REaCT-G and G2
| REaCT-G and G2 |
Duration of G-CSF treatment (5 days vs 7/10 days) during chemotherapy Principal Investigator(s): Dr. Mark Clemons |
| ClinicalTrials.gov: NCT02428114 | |
| In patients with early-stage breast cancer, chemotherapy has substantially improved survival rates. Improvements in outcomes, however, are compromised by the considerable toxicities associated with chemotherapy, the most notable being neutropenia. Neutropenia is the presence of abnormally few white blood cells, leading to increase susceptibility to infection and can require hospitalization and need for intravenous antibiotics and is sometimes fatal. Febrile neutropenia (FN) can also be associated with treatment delays and dose reductions, potentially compromising treatment efficacy. Patients can receive medication to reduce the risk of FN such as Neupogen (filgrastim) as a daily injection for 5, 7 or 10 days. Since there is genuine uncertainty among healthcare professionals as to which administration schedule of Neupogen is the best for patients, this randomized trial compared 5, 7 or 10 days of Neupogen. | |
|
Sites: Cancer Centre of Southeastern Ontario (Kingston) London Health Sciences Centre Northeast Cancer Centre (Sudbury) Southlake Regional Health Centre (Newmarket) The Ottawa Hospital Thunder Bay Regional Health Sciences Centre |
|
|
Publications: Systematic Review:
Patient and Physician Surveys:
Clinical Trial results:
|
|